Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Status:
Suspended
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This study proposes that the addition of statins reduces the treatment delays or early
discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive
breast being treated with anti-HER2 therapy.